Christopher Viehbacher

Independent Non-Executive Director

Mr Viehbacher is the Managing Partner of Gurnet Point Capital. He is also the Chairman of the Board of Directors of Boston Pharmaceuticals and of Vedanta as well as the Vice-Chair of Nuvelution. He is a member of the Board of Directors of Pronutria. Mr Viehbacher is a Trustee of Northeastern University and the Past-Chair of the CEO Roundtable on Cancer.

Mr Viehbacher is the former CEO of Sanofi, a Paris listed Fortune 50 Biopharmaceutical Company and the former Chairman of Genzyme. During his six year tenure, Sanofi underwent a significant business transformation, completing over $30 billion of acquisitions, most notably, Genzyme Ltd. Prior to joining Sanofi, Mr Viehbacher spent 20 years at GlaxoSmithKline, ultimately serving as President of GSK’s North American pharmaceutical division and as a member of the Board of Directors of GSK plc. He began his career with PriceWaterhouseCoopers LLP and qualified as a Chartered Accountant in Canada.

Mr Viehbacher has co-chaired the CEO Roundtable on Neglected Diseases with Bill Gates, an organization that led to over 1.3 billion people being treated for such diseases free of charge. He was the Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). At the World Economic Forum at Davos, he was a Chair of the Health Governors and co-chaired an initiative to create a Global Charter for Healthy Living. He was also a member of the International Business Council. Mr Viehbacher has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France’s highest civilian honour, the Legion d’Honneur. Various awards form the Thompson Reuters/Excel Investor Survey, including top Chief Executive Officer and top European company, have recognised his commitment to investor relations.

UPDATED OCTOBER 2016